Tirzepatide and Your Kidneys: Mounjaro & Zepbound Guide

Short answer: Tirzepatide is the medicine in Mounjaro and Zepbound. It does not need a dose change if your kidneys are weak, and it is not considered directly toxic to the kidney (acute kidney injury has been reported, but almost always from dehydration, not a direct toxic effect). But it has not yet been proven to protect the kidney the way one related drug (semaglutide) has — those studies are still running. The real day-to-day kidney risk with tirzepatide is dehydration from nausea, vomiting, or diarrhea, which can strain the kidneys, especially if you also take water pills or blood-pressure medicines.

Written and medically reviewed by Dr. Amir S. Naderi, MD, FASN — board-certified in Internal Medicine and Nephrology (ABIM), trained at UT Southwestern and Johns Hopkins, with a clinical focus on obesity medicine. Last updated: July 8, 2026.

3 things to remember

Tirzepatide usually does not need a kidney-dose adjustment.
The main kidney risk is dehydration from stomach (GI) side effects.
Kidney-protection data for tirzepatide are promising, but not yet proven — unlike semaglutide in diabetes and CKD.

What tirzepatide is, in plain terms

Tirzepatide is the active drug inside two brand-name injections:

Mounjaro — approved by the FDA to treat type 2 diabetes.
Zepbound — approved for weight management (and, separately, for obstructive sleep apnea in adults with obesity).

Both pens contain the same medicine. The difference is mostly the label and, often, what your insurance will cover.

Tirzepatide is a once-a-week shot. It works on two gut hormones at once — GLP-1 and GIP. (You may see it called a “dual agonist.” An agonist is a drug that switches a receptor on.) Semaglutide — the medicine in Ozempic and Wegovy — works on just one of those hormones (GLP-1). That difference matters for weight and blood sugar. For the kidney, the honest headline is simpler and more important: we have far less long-term kidney data on tirzepatide than we do on semaglutide.

If you take Ozempic or Wegovy, our companion guide covers that drug in detail: Semaglutide (Ozempic/Wegovy) and Your Kidneys.

The most important thing to know: the kidney evidence is not the same for both drugs

This is where a lot of online writing gets sloppy. So let’s be precise about what we know, who it applies to, and what is still open.

What we know (semaglutide): In a large trial called FLOW, people with type 2 diabetes plus chronic kidney disease (CKD) who took semaglutide 1.0 mg had fewer major kidney events — things like kidney failure or a big drop in kidney function — than people on placebo. The risk of the main kidney outcome was about 24% lower (hazard ratio 0.76). In plain numbers, roughly 1 in 20 people treated for about 3.4 years avoided a major kidney event (number needed to treat ≈ 20 — an approximation calculated from the trial’s published event counts, 331 vs 410 events). These are hard endpoints — real kidney outcomes, not just lab numbers.

Who that applies to: People with type 2 diabetes and existing CKD, taking semaglutide. It does not automatically apply to tirzepatide, and it does not automatically apply to people without diabetes.

What is still open (tirzepatide): There is no completed trial showing that tirzepatide prevents kidney failure or slows CKD to a hard endpoint. The evidence we have for tirzepatide and the kidney is at the surrogate level — meaning it moved lab markers (like protein in the urine and the rate of kidney-function decline) in a favorable direction, but it has not yet been shown to change what patients care about most: staying off dialysis and living longer.

A dedicated kidney trial of tirzepatide in people with overweight or obesity and CKD (with or without diabetes) is ongoing — but note it is a phase-2 mechanistic study (TREASURE-CKD, ClinicalTrials.gov NCT05536804; about 140 participants over ~56 weeks), not a large hard-outcome trial designed to prove fewer cases of dialysis, kidney failure, or kidney death. Until it reports, calling tirzepatide “kidney-protecting” would be getting ahead of the evidence.

A note on a common mix-up: You may see the trial “TRIUMPH-Outcomes” (NCT06383390) cited for tirzepatide. That trial actually studies retatrutide, a different Eli Lilly drug — not tirzepatide. We flag this because getting the study right matters.

📬 Keep up as the science changes

New studies on weight-loss drugs and kidney health are coming out constantly — and the headlines are often wrong. New studies on weight loss drugs and kidney health, explained monthly. Sign up for the newsletter →

Semaglutide vs. tirzepatide: what the kidney evidence actually says

Here is the comparison in one place. Notice the “Endpoint type” and “Status” columns — that is where the two drugs differ most for the kidney.

Drug	Key kidney study	Population studied	Endpoint type	Status for the kidney
Semaglutide (Ozempic/Wegovy)	FLOW (NEJM 2024)	Type 2 diabetes + CKD	Hard kidney endpoints (kidney failure, ≥50% eGFR loss, kidney/CV death)	Proven benefit in this group: ~24% relative risk reduction (NNT ≈ 20 over ~3.4 yrs)
Tirzepatide (Mounjaro/Zepbound)	SURPASS-4 renal analysis (2022); pooled SURPASS-1–5 albuminuria analysis (2025)	Type 2 diabetes (high cardiovascular risk)	Surrogate (slower eGFR decline, less urine protein)	Encouraging but not proven on hard outcomes
Tirzepatide	SUMMIT (2025)	Heart failure (preserved EF) + obesity	Secondary/surrogate kidney signals	Supportive, not a kidney-outcome trial
Tirzepatide	NCT05536804 (TREASURE-CKD) — phase-2 mechanistic study	Overweight/obesity + CKD, ± diabetes	Kidney outcomes	Ongoing — phase 2, ~140 people; mechanistic, not a hard-outcome trial
Tirzepatide — obesity without diabetes	SURMOUNT-1 / -2 post-hoc (JASN 2025)	—	—	Reduced albuminuria, no adverse eGFR change — surrogate only

The takeaway: If your main goal is proven kidney protection and you have type 2 diabetes with CKD, semaglutide currently has the stronger evidence. Tirzepatide may turn out to help the kidney too — the early signals point that way — but as of today that is a reasonable hope, not a proven fact. Your doctor may still choose tirzepatide for good reasons (blood sugar, weight, heart failure, sleep apnea, side-effect tolerance, or cost/coverage). That is a shared decision.

Source note: the SURPASS-4 renal analysis (Heerspink et al., Lancet Diabetes Endocrinol 2022) was a post-hoc, open-label comparison of tirzepatide vs. insulin glargine in people with type 2 diabetes at high cardiovascular risk (n≈1,995). Tirzepatide lowered urine albumin (between-group UACR −31.9%), reduced new heavy albuminuria (HR 0.41), and slowed eGFR decline — but these are surrogate/exploratory endpoints, not proof that fewer people reach kidney failure. In people with obesity (with or without diabetes), a 2025 JASN post-hoc analysis of SURMOUNT-1 and SURMOUNT-2 found reduced albuminuria with no adverse change in eGFR — again, surrogate signals, not hard outcomes.

Does tirzepatide need a dose change if my kidneys are weak?

No. Tirzepatide does not require a dose adjustment for reduced kidney function — including in people on dialysis (end-stage kidney disease). The drug is broken down by the body’s normal protein-recycling process, so it is not cleared by the kidneys. Weak kidneys do not cause it to build up.

That is genuinely reassuring, and it is different from many older medicines. But “no dose change needed” is not the same as “no kidney precautions needed.” The precautions are about side effects, not drug buildup — and that is the next section.

The real kidney risk with tirzepatide: dehydration and “prerenal” injury

Most kidney trouble people run into on tirzepatide (or semaglutide) is not the drug attacking the kidney. It is dehydration.

Tirzepatide commonly causes nausea, vomiting, and diarrhea, especially in the first weeks and after each dose increase. If you lose a lot of fluid and don’t replace it, less blood reaches the kidneys. Doctors call this prerenal acute kidney injury — “prerenal” meaning the problem is upstream of the kidney (not enough blood flow), and “acute kidney injury” (AKI) meaning a sudden, usually reversible drop in kidney function.

The risk goes up sharply when tirzepatide’s stomach side effects land on top of other medicines that also lower blood flow to the kidney. Watch for this combination:

Diuretics (“water pills,” e.g., furosemide, hydrochlorothiazide)
ACE inhibitors or ARBs (blood-pressure/kidney medicines ending in -pril or -sartan)
NSAIDs (over-the-counter pain relievers like ibuprofen or naproxen)

Each of these is fine on its own for the right person. But if you get sick and dehydrated while taking them together with tirzepatide, they can stack up and stress the kidney at the same time.

A simple “sick-day plan”

Talk to your own doctor about a plan that fits you. A common, sensible version looks like this:

When to pause: If you can’t keep fluids down for more than a day — repeated vomiting, heavy diarrhea, or clear signs of dehydration (dizziness on standing, very dark urine, little or no urination) — it may be time to temporarily hold certain medicines.
What may be paused (with your doctor’s OK): the diuretic, the ACE inhibitor/ARB, the NSAID, and sometimes an SGLT2 inhibitor (another kidney/diabetes drug) — until you’re eating and drinking normally again.
What to do: sip fluids, use oral rehydration if needed, and call your clinic. If you can’t keep water down at all or feel very unwell, seek urgent care.
Do not stop or change any prescribed medicine on your own without medical advice — see the disclaimer below.

This plan is worth setting up before you get sick, not during. Keep a short written list of which of your medicines to hold and who to call.

Why your creatinine (and eGFR) can be misleading on tirzepatide

This is one of the most important — and most misunderstood — points, so read it twice.

Your kidney function is usually estimated from a blood test called creatinine, which is turned into a score called eGFR (estimated glomerular filtration rate — basically, a percentage-style estimate of how well the kidneys filter).

Here’s the catch: creatinine is a waste product of muscle. The more muscle you carry, the more creatinine you make. When you lose a lot of weight quickly — and especially if some of that loss is muscle — you make less creatinine. On the lab report, lower creatinine makes your eGFR look higher, as if your kidneys improved.

Sometimes your kidneys really did improve (losing excess weight can genuinely help). But sometimes the number moved simply because you lost muscle — the kidney itself didn’t change. Relying on creatinine alone can make you think your kidneys are doing better than they are.

What helps: a second marker called cystatin C, which is much less dependent on muscle mass than creatinine (though not perfect, and influenced by other factors). If your weight is dropping fast and your creatinine-based eGFR is bouncing around, ask your doctor whether a cystatin C check (or a combined creatinine-cystatin C eGFR) would give a truer picture. This is exactly the kind of nuance a kidney-aware clinician watches for.

(Going deeper on this: Why is my creatinine up — or down — on Mounjaro?)

Muscle loss and protein: the quiet issue

Fast weight loss on tirzepatide is not all fat. A meaningful share can be muscle, particularly if you don’t eat enough protein or don’t do resistance exercise. For kidney patients, this creates a real tension:

Weight-loss medicine tends to reduce appetite, so people eat less protein.
But keeping muscle usually requires enough protein.
Meanwhile, in advanced CKD, doctors sometimes advise limiting protein to reduce the kidney’s workload.

So how much protein is right? It genuinely depends on your stage of kidney disease, whether you’re on dialysis, and your muscle status — there is no single number that fits everyone. This is a conversation to have specifically with a clinician who knows your kidney numbers, ideally a renal dietitian.

Two practical points nearly everyone agrees on: don’t lose muscle if you can avoid it, and resistance exercise (even light strength work) helps protect muscle during weight loss.

(More on this: How much protein on a GLP-1 if I have CKD? and Why am I losing muscle on Zepbound?)

Compounded tirzepatide and your kidneys

“Compounded” tirzepatide is a version mixed by a compounding pharmacy rather than made by the manufacturer (Eli Lilly). During the 2023–2024 shortage, compounded versions were widely sold, often cheaply and through telehealth sites. That situation has changed, and kidney patients in particular should be careful.

Where things stand (U.S., 2026):

The FDA declared the tirzepatide shortage resolved in December 2024.
Because the shortage ended, the legal basis for mass-compounding went away. The FDA ended its “enforcement discretion” for smaller (503A) pharmacies on February 18, 2025, and for larger (503B) outsourcing facilities on March 19, 2025.
In 2026, the FDA proposed going further — permanently excluding tirzepatide (and semaglutide and liraglutide) from the list of drugs that outsourcing facilities may compound in bulk.

In short: broad, cheap compounded tirzepatide is no longer a legal, routine option the way it was in 2024. Narrow, patient-specific compounding may still occur in limited situations, but the era of easy online “compounded tirzepatide” is closing.

Why kidney patients should be extra cautious with compounded versions:

Dosing errors. Many compounded products come in multi-dose vials, and patients have to draw up the dose themselves. The FDA received hundreds of adverse-event reports tied to compounded GLP-1 drugs — including more than 320 for compounded tirzepatide by early 2025 — a tally the FDA has since updated to more than 730 as of May 31, 2026 — and many involved people accidentally taking too much, sometimes requiring hospitalization. An overdose can trigger severe vomiting and diarrhea → dehydration → acute kidney injury. Careful, gradual dose increases matter more, not less, when your kidneys are vulnerable.
No independent quality control. Compounded products are not FDA-approved and are not tested for purity, potency, and sterility the way the branded pens are. Unknown impurities are a special concern for people whose kidneys clear the body’s waste less efficiently.
Inconsistent strength. Safe kidney-aware use depends on a known, steady dose you can titrate slowly. Compounded products can vary batch to batch, which makes careful titration harder.

If cost is the reason you’re considering a compounded version, talk to your clinician about FDA-approved options first — including manufacturer savings programs, and, in the U.S., how insurance and prior authorization may cover Mounjaro or Zepbound for your situation.

The strongest argument against worrying — and our answer

The steelman (the best case that kidney worry is overblown): “Tirzepatide isn’t cleared by the kidneys, needs no dose change even in dialysis, and every early signal — less protein in the urine, slower eGFR decline — points the same way as semaglutide, which is proven to protect the kidney. Both are incretin drugs. Isn’t it overly cautious to keep saying ‘not proven’? In practice, won’t tirzepatide help the kidney too?”

Our answer: It may well help — we think the odds are reasonable, and the early data are encouraging. But medicine has repeatedly been surprised when a drug that improved a lab marker failed to improve real outcomes, or caused harm that only a large trial revealed. “Same drug class, similar early signals” is a hypothesis, not proof — and tirzepatide is not identical to semaglutide (it hits an extra receptor, GIP). The responsible position is to use tirzepatide for what it’s approved and proven to do (blood sugar control, weight management, and — in the U.S. — obstructive sleep apnea in adults with obesity (its heart-failure data in HFpEF with obesity are encouraging, but that is not a broad approved indication)), to manage the real, present risk (dehydration and prerenal AKI), and to wait for the dedicated kidney trial before claiming proven kidney protection. Honest uncertainty is not the same as pessimism. It’s what lets you make a decision you won’t regret.

Questions to bring to your doctor

Given my kidney numbers and diabetes status, is semaglutide or tirzepatide the better fit for me?
Which of my medicines (water pills, blood-pressure pills, NSAIDs, SGLT2 inhibitors) should I hold on sick days?
Should I have a cystatin C check as I lose weight, so we don’t misread my kidney function?
How do we protect my muscle — how much protein, and what kind of exercise?
If cost is an issue, what FDA-approved and insurance/prior-authorization options do I have?

Frequently asked questions

1. Does Mounjaro or Zepbound damage the kidneys? Tirzepatide is not considered directly toxic to the kidney, and it needs no dose change even for weak kidneys. The main kidney risk is indirect: dehydration from nausea, vomiting, or diarrhea can cause a temporary, usually reversible kidney injury — more likely if you also take water pills, ACE inhibitors/ARBs, or NSAIDs.

2. Why is my creatinine up on Mounjaro? A rise in creatinine most often reflects dehydration from stomach side effects, not the drug harming the kidney. Rehydrating usually brings it back down. Because creatinine also depends on muscle, rapid weight loss can make the number swing either way — ask about a cystatin C check to see the truer picture. If your creatinine keeps rising, contact your clinician.

3. Can I take tirzepatide if I have chronic kidney disease (CKD)? Often yes — there is no required dose change for reduced kidney function, including dialysis. But it should be done with a sick-day plan and, ideally, monitoring. Note that proven hard-endpoint kidney protection has been shown for semaglutide (in diabetes + CKD), not yet for tirzepatide. Decide with your doctor.

4. Is dehydration from Zepbound dangerous for my kidneys? It can be. Significant fluid loss lowers blood flow to the kidneys and can cause prerenal acute kidney injury, especially alongside diuretics, ACE inhibitors/ARBs, or NSAIDs. Have a sick-day plan, sip fluids, and call your clinic if you can’t keep fluids down. (See our full guide: Is dehydration from Zepbound dangerous for my kidneys?)

5. Does tirzepatide protect the kidneys like Ozempic? Not proven yet. Semaglutide has hard-endpoint kidney data (the FLOW trial). Tirzepatide has only surrogate signals so far (less urine protein, slower eGFR decline). A dedicated tirzepatide kidney trial is ongoing.

6. Do I need to stop tirzepatide before surgery? Under 2024 multisociety guidance (from the American Society of Anesthesiologists, the American Gastroenterological Association, and others), most patients can continue their GLP-1/GIP drug before elective surgery, using a risk-based approach rather than stopping it automatically. People at higher risk of delayed stomach emptying (for example, still increasing the dose, or having significant nausea/vomiting) may be advised to take extra precautions, such as a 24-hour liquid diet beforehand. Always tell your surgeon and anesthesiologist that you take tirzepatide — the final call is theirs.

7. Is compounded tirzepatide safe if I have kidney disease? It carries extra risk. Compounded versions aren’t FDA-quality-checked, can vary in strength, and are linked to dosing errors that can cause overdose, severe dehydration, and acute kidney injury. As of 2026, broad compounding is also no longer a routine legal option in the U.S. Prefer FDA-approved Mounjaro or Zepbound and ask about coverage.

References

Show sources

1. Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). N Engl J Med. 2024. (ClinicalTrials.gov NCT03819153.) — Primary composite kidney outcome HR 0.76 (95% CI 0.66–0.88); 331 vs 410 events; median follow-up 3.4 years.
2. Heerspink HJL, et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial (post-hoc analysis). Lancet Diabetes Endocrinol. 2022. — Surrogate/exploratory endpoints; between-group UACR −31.9%; new macroalbuminuria HR 0.41.
3. Tirzepatide and reduced albuminuria — pooled post hoc analysis of SURPASS-1–5. Diabetes Care. 2025;48(3):430. — Surrogate endpoint (albuminuria).
4. Interplay of CKD and tirzepatide effects in HFpEF and obesity (SUMMIT). J Am Coll Cardiol. 2025. — Secondary/surrogate kidney analysis.
5. ClinicalTrials.gov NCT05536804 — A Study of Tirzepatide in Participants With Overweight or Obesity and CKD With or Without Type 2 Diabetes. Ongoing.
6. Effects of Renal Impairment on the Pharmacokinetics of Tirzepatide. Clin Pharmacokinet. 2021. — No PK change across renal impairment/ESRD; no dose adjustment required.
7. Mounjaro / Zepbound U.S. Prescribing Information (accessdata.fda.gov). — Renal impairment: no dose adjustment; monitor renal function with severe GI reactions.
8. FDA. Resolution of Shortages of Tirzepatide Injection (Dec 2024). — 503A discretion ended Feb 18, 2025; 503B ended Mar 19, 2025.
9. FDA / trade coverage (2026). Proposed exclusion of semaglutide, tirzepatide, liraglutide from the 503B bulks list.
10. Note: TRIUMPH-Outcomes (NCT06383390) studies retatrutide, not tirzepatide, and is cited here only to correct a common misattribution.

Educational information only — not medical advice. Never change or stop a prescribed medication without talking to your doctor. This page describes general patterns, not personal recommendations, and does not create a doctor–patient relationship.

Tirzepatide (Mounjaro and Zepbound) and Your Kidneys